View in EDS PDF Full Text

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.

Saved in:
Bibliographic Details
Title: Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Authors: Ricci, Francesca1, Guffanti, Federica1, Damia, Giovanna1 damia@marionegri.it, Broggini, Massimo1
Source: Molecular Cancer. 5/30/2017, Vol. 16, p1-6. 6p. 2 Charts, 3 Graphs.
Database: Academic Search Ultimate
Description
ISSN:14764598
DOI:10.1186/s12943-017-0662-3